March 17, 2018 1:05 AM ET


Company Overview of Corium International, Inc.

Company Overview

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company’s products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 ...

235 Constitution Drive

Menlo Park, CA 94025

United States

Founded in 1995

213 Employees





Key Executives for Corium International, Inc.

President, CEO & Director
Age: 65
Total Annual Compensation: $462.5K
Chief Financial Officer
Age: 55
Total Annual Compensation: $366.5K
Chief Business Officer
Age: 50
Total Annual Compensation: $335.1K
Compensation as of Fiscal Year 2016.

Corium International, Inc. Key Developments

Corium International, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2017

Corium International, Inc. reported unaudited consolidated earnings results for the first quarter ended December 31, 2017. For the quarter, total revenues were $9,315,000 against $6,968,000 a year ago, Product revenues increased for the first quarter of fiscal 2018 compared to same period of fiscal 2017, primarily as a result of an increase in revenues from Procter &Gamble for Crest(R) Whitestrips and an increase in revenues from Mayne Pharma for Fentanyl transdermal delivery system (TDS), partially offset by a reduction in demand from Mayne Pharma for Clonidine TDS. Contract research and development revenues increased for the first quarter of fiscal 2018 compared to the same period of fiscal 2017, primarily resulting from increased activities supporting Agile's development program for Twirla. Loss from operations was $11,289,000 against $8,413,000 a year ago. Loss before income taxes was $13,290,000 against $10,427,000 a year ago. Net loss and comprehensive loss was $13,292,000 against $10,429,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.37 against $0.46 a year ago.

Corium International, Inc. to Report Q1, 2018 Results on Feb 08, 2018

Corium International, Inc. announced that they will report Q1, 2018 results at 5:00 PM, Eastern Standard Time on Feb 08, 2018

Corium International, Inc., Q1 2018 Earnings Call, Feb 08, 2018

Corium International, Inc., Q1 2018 Earnings Call, Feb 08, 2018

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Corium International, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at